<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>School of Clinical Sciences</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C7DF8B53-123F-442B-BF84-A5FD014A0336"><gtr:id>C7DF8B53-123F-442B-BF84-A5FD014A0336</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:surname>Chapman</gtr:surname><gtr:orcidId>0000-0001-7777-6817</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4A9E1FC3-1237-4AE1-8A3F-9633FDA1FFC6"><gtr:id>4A9E1FC3-1237-4AE1-8A3F-9633FDA1FFC6</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Savill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/43624727-2D66-49AE-8923-426DD4CDD141"><gtr:id>43624727-2D66-49AE-8923-426DD4CDD141</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Seckl</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2E71ABCC-AE87-41CE-AFD7-3FD228CDA2EF"><gtr:id>2E71ABCC-AE87-41CE-AFD7-3FD228CDA2EF</gtr:id><gtr:firstName>Mohini</gtr:firstName><gtr:surname>Gray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800235"><gtr:id>0300C403-BC57-4C2B-80C5-78B4E745207F</gtr:id><gtr:title>How does 11B-hydroxysteroid dehydrogenase type I limit inflammation?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800235</gtr:grantReference><gtr:abstractText>Anti-inflammatory steroids (glucocorticoids) are among the most commonly prescribed drugs in the UK. Glucocorticoids are also produced naturally by the body, in both active (cortisol) and inactive (cortisone) forms, which help to control inflammation. The inactive cortisone is converted to active cortisol by an enzyme, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which thus acts to amplify active steroid levels in specific tissues. Levels of 11beta-HSD1 are rapidly increased in inflamed tissues, where it may promote the successful resolution of inflammation by increasing ?local? glucocorticoid action. This suggests that 11beta-HSD1 is anti-inflammatory. We have shown that mice lacking 11beta-HSD1 have an exaggerated (more severe and earlier onset) inflammatory response. We now aim to identify the cells responsible for the anti-inflammatory effects of 11beta-HSD1 and determine the mechanism by which it exerts these important effects. The results will be of potential therapeutic importance to target anti-inflammatory treatment.</gtr:abstractText><gtr:technicalSummary>Glucocorticoid (steroid) hormones circulate in the blood and have potent anti-inflammatory effects. However, intracellular glucocorticoid concentrations can differ greatly from blood levels due to metabolism by 11beta-hydroxysteroid dehydrogenase (11beta-HSD), an enzyme that interconverts active and inactive glucocorticoids. Two isozymes exist; 11beta-HSD1 predominantly reactivates glucocorticoids by converting inert 11-keto-glucocorticoids (cortisone in humans, 11-dehydrocorticosterone in rodents) into active forms (cortisol, 11-dehydrocorticosterone), thus amplifying glucocorticoid action in cells and tissues in which it is expressed. Levels of 11beta-HSD1 are rapidly increased in inflamed tissues and in macrophages, where it may promote the successful resolution of inflammation by increasing ?local? glucocorticoid action. Recently we have shown that mice lacking 11beta-HSD1 have an exaggerated (more severe and earlier onset) acute inflammatory response. These data allow the hypothesis that 11beta-HSD1 represents an endogenous anti-inflammatory mechanism engaged early during an inflammatory response that limits the onset and severity of inflammation and ?programmes? the trajectory of the subsequent resolution. We now aim to determine which cells and mechanisms are responsible for the acute anti-inflammatory effects of 11beta-HSD1, focussing on myeloid immune cells (mast cells, monocytes/macrophages) versus the host tissues (notably vasculature and fibroblasts).</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>477103</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Microbiome and bioinformatics</gtr:description><gtr:id>1619DF09-DA95-472A-9457-8285AAB68C68</gtr:id><gtr:impact>Publication: PMID 27885053
Funding application will be submitted in May 2017</gtr:impact><gtr:outcomeId>58b56c41b8c3e3.19073702-1</gtr:outcomeId><gtr:partnerContribution>The bioinformatic analysis of the data and interpretation.</gtr:partnerContribution><gtr:piContribution>We provided the research question and the biological materials, the sequencing was carried out in the genome facility (MRC funded) in Edinburgh.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public lecture series</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9E63DF75-5C22-4FFC-B40F-2C2D60DA8735</gtr:id><gtr:impact>Co-organiser of public lecture series (4 to 5 lectures annually) from 2010-2012; sole organiser from 2013 &amp;quot;Let's talk about....&amp;quot; aimed at the general public and part of &amp;quot;Pathways to the professions&amp;quot;. Sponsored by the MRC. Audiences (2013/14) &amp;gt;100. See http://www.cvs.med.ed.ac.uk/lets-talk

Forms part of &amp;quot;Pathways to the Professions&amp;quot; widening participation efforts to help school pupils in entry to medical school.</gtr:impact><gtr:outcomeId>jVQTCLyb2xj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cvs.med.ed.ac.uk/lets-talk</gtr:url><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A line of transgenic mice created by crossing LysM-Cre transgenic mice (which express Cre recombinase in myeloid cells) with &amp;quot;floxed&amp;quot; 11beta-hydroxysteroid dehydrogenase type 1 mice.</gtr:description><gtr:id>102011B1-E473-4B44-9D11-584C4AE929DB</gtr:id><gtr:impact>Research currently ongoing to detemine whether myeloid cell 11beta-HSD1 plays a role in the inflammatory phenotype.</gtr:impact><gtr:outcomeId>KGNvGDLzm5B</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>myeloid cell-specific knock-out of 11beta-hydroxysteroid dehydrogenase type 1</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>909A3942-3C53-432D-B2B3-7E743A86066C</gtr:id><gtr:title>The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe056c0ceabcf854a38d1b542d92f70"><gtr:id>cbe056c0ceabcf854a38d1b542d92f70</gtr:id><gtr:otherNames>Chapman KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>3BFBADB63D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E0D4A59-6F26-4C25-BA8F-3A4BA65C85C0</gtr:id><gtr:title>11?-Hydroxysteroid Dehydrogenase Type 1 Is Expressed in Neutrophils and Restrains an Inflammatory Response in Male Mice.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9821420b13976ee2721c4f260b8720d"><gtr:id>b9821420b13976ee2721c4f260b8720d</gtr:id><gtr:otherNames>Coutinho AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>585d67373b9730.28814677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C71F7B3C-4A00-4463-925C-89FC269B25D1</gtr:id><gtr:title>Macrophage 11?-HSD-1 deficiency promotes inflammatory angiogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0355658aee7a567caa922e6adbda88b6"><gtr:id>0355658aee7a567caa922e6adbda88b6</gtr:id><gtr:otherNames>Zhang Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>5a7322b22943f2.16604744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF7AE49E-BF1B-4023-A14F-E600EBC9B452</gtr:id><gtr:title>The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9821420b13976ee2721c4f260b8720d"><gtr:id>b9821420b13976ee2721c4f260b8720d</gtr:id><gtr:otherNames>Coutinho AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>SKxpcyfBVUZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84BF6A1C-8C6A-474C-8651-5CAF8844EB72</gtr:id><gtr:title>Mast cells express 11?-hydroxysteroid dehydrogenase type 1: a role in restraining mast cell degranulation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9821420b13976ee2721c4f260b8720d"><gtr:id>b9821420b13976ee2721c4f260b8720d</gtr:id><gtr:otherNames>Coutinho AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>TW4R4WpHLnP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>373DE2D9-43C1-4377-A57B-94A64B5D1E82</gtr:id><gtr:title>11?-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3e158917a26b4fec77993a8a5ffc6d6"><gtr:id>d3e158917a26b4fec77993a8a5ffc6d6</gtr:id><gtr:otherNames>Kipari T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_12947_27_23303209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F9983B2-C622-4561-A36A-CB1C187E9851</gtr:id><gtr:title>11?-Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9821420b13976ee2721c4f260b8720d"><gtr:id>b9821420b13976ee2721c4f260b8720d</gtr:id><gtr:otherNames>Coutinho AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>Un1XnJV6oDo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB5B2E8D-D65B-4F31-A73A-037780D1A61F</gtr:id><gtr:title>Changing glucocorticoid action: 11?-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe056c0ceabcf854a38d1b542d92f70"><gtr:id>cbe056c0ceabcf854a38d1b542d92f70</gtr:id><gtr:otherNames>Chapman KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>HPQ2WfJfNmr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>009FA39F-8E54-4052-A9E4-D3F0BEAFE9BE</gtr:id><gtr:title>11?-hydroxysteroid dehydrogenase type 1 has no effect on survival during experimental malaria but affects parasitemia in a parasite strain-specific manner.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c36de11332cfa6f3a7a5ee991d3eedfb"><gtr:id>c36de11332cfa6f3a7a5ee991d3eedfb</gtr:id><gtr:otherNames>Vandermosten L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a361b5ab1e7c2.70993069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14EEE050-4DD3-42D3-802C-68AC03CDF524</gtr:id><gtr:title>11?-hydroxysteroid dehydrogenase-1 deficiency alters brain energy metabolism in acute systemic inflammation.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13612d272764df84675aaca216a4839a"><gtr:id>13612d272764df84675aaca216a4839a</gtr:id><gtr:otherNames>Verma M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>5a7328751e7288.16302016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ABF3DE7-6722-468F-A69C-1777DD362911</gtr:id><gtr:title>11?-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.</gtr:title><gtr:parentPublicationTitle>Physiological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/067bfa25ccae28fd047321636e49bd20"><gtr:id>067bfa25ccae28fd047321636e49bd20</gtr:id><gtr:otherNames>Chapman K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-9333</gtr:issn><gtr:outcomeId>pm_12947_27_23899562</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800235</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>